Navigation Links
Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
Date:11/17/2010

ained at the Cardiovascular Center in Aalst (Aalst, Belgium).

In accordance with the Bayh-Dole Act, Mayo Clinic has licensed the technology underlying C-Cure to Cardio 3 Biosciences and received an equity position in the company in the context of the license. Mayo Clinic, and the inventors of the technology, Drs. Andre Terzic and Atta Behfar, have a financial interest associated with the technology related to this research. While no royalties have accrued to date, Mayo Clinic has rights to receive future royalties which will be shared with Drs. Terzic and Behfar in accordance with Mayo Clinic Royalty Sharing policy.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or rep
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
2. Cardio3 BioSciences Announces Promising Pre-Clinical Data for Proprietary C-Cath(R) Catheter
3. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
4. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
6. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
7. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
8. Ambit Biosciences Strengthens Board of Directors and Executive Team
9. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
10. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN MARCOS, Texas , Nov. 21, 2014 /PRNewswire/ ... industrial hemp containing low THC, announces they are now ... is comparable to Charlotte,s Web type strains grown in ... symptoms from other neurological disorders, such as Parkinson,s, MS, ... waiting for US laws to pass, because imported CBD ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... Inc. (NYSE: LDR) announced today that its Board of ... share for the second quarter of fiscal 2012. The dividend will ... on March 9, 2012. About Landauer ... services to determine occupational and environmental radiation exposure and is ...
... BRUSSELS, Feb. 28, 2012 Eli Lilly and Company (NYSE: ... global Innovation Starts Here initiative which supports Lilly,s commitment to ... the world. Two key components of this ... Innovation Fellowship Awards. Through both, Lilly scientists will collaborate with ...
Cached Medicine Technology:Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 2Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 3Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 4Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 5
(Date:11/21/2014)... CDT PLUS! 2015 represents ... includes everything needed to process dental insurance claims. ... , CDT 2015 codes are mandatory for reporting dental ... December 31, 2014. Dental professionals must use HIPAA mandated ... claims. There are significant changes in the CDT coding ...
(Date:11/21/2014)... 21, 2014 TopConsumerReviews.com recently awarded ... industry leader in the relief of depression ... feelings of sadness and depression each year and ... choices. Often, prescription drugs can produce worse side ... are expensive and require regular follow-up visits with ...
(Date:11/21/2014)... FL (PRWEB) November 21, 2014 According ... issued on June 11th, 2014, the inflating system ... rupture when the airbag inflates. The force of inflation ... shrapnel, and the metal shards may pierce the airbag’s ... vehicle’s cabin. , According to a Bloomberg Business ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... only ISO verified healthcare professional panel, today announced two important ... appointment of Roni DasGupta as President of Market Research, Americas ... Market Research, Europe. , Ms. DasGupta joined M3 ... President and most recently Head of Sales. Roni has ...
(Date:11/21/2014)... Dennis Thompson HealthDay ... Injecting beads of gel into the wall of a still-beating ... with severe heart failure, according to a new study. ... oxygen levels and were able to walk hundreds of feet ... Douglas Mann. He is chief of the cardiovascular division at ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3
... to open blocked heart arteries a key question has ... expensive drug, abciximab, justified over use of the less-expensive ... be published in the current edition of Value in ... an e-publication, offers clinicians the first large-scale contemporary study ...
... On the Wings to Patient Safety: Innovative Solutions and Tools set ... ... Mich., Sept. 10 The Risk Management and,Patient Safety Institute (RM&PSI) ... conference. The RM&PSI, a,subsidiary of FinCor Holdings Inc. (http://www.fincorholdings.com ), ...
... accuracy and turn-around time for reimbursement, WAYNE, ... in,health information management (HIM) services and technologies, today,announced ... 2X. The key enhancement to PrecyseCode 2X is ... of the medical record,and greater efficiency and speed ...
... Wolf Haldenstein Obtain Third-Largest Settlement,in Securities Fraud Case ... Sept. 10 Judge Morris E.,Lasker of the ... has,granted final approval of a $52.5 million settlement ... Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: SEPR ...
... well known healthcare industry executive to start October ... Corporation,(NYSE: STE ) today announced that its ... 53, president and chief executive officer, effective,October 1, ... Company,s Board,effective that date. (Photo: http://www.newscom.com/cgi-bin/prnh/20070910/CLM134 ...
... Institute are the first to discover a mechanism that ... cycle and survival. Their research may result in identification ... , The results of the study appear ... PhD, assistant professor of hematology and oncology at Emory ...
Cached Medicine News:Health News:The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 2Health News:Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals 3Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 2Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 3Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 4Health News:STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer 5Health News:Emory researchers identify signaling protein for multiple myeloma 2Health News:Emory researchers identify signaling protein for multiple myeloma 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: